Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder
Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points
SAGE-217 is currently being investigated in the Phase 3 MOUNTAIN trial for the treatment of MDD, with results expected in Q4 2019 or Q1 2020
Results published in NEJM also include additional data from multiple secondary endpoints, all of which generally favored SAGE-217 at the end of treatment (Day 15). In the study, SAGE-217 was generally well tolerated with a safety profile consistent with that seen in earlier SAGE-217 trials. Overall reports of treatment emergent adverse events (TEAEs) were 53.3% in the SAGE-217 group and 45.5% in the placebo group. No serious adverse events or deaths occurred during the trial.
“The findings published in the
Major depressive disorder causes a persistent feeling of sadness and loss of interest in daily activities, often affecting how a person feels, thinks and behaves, and can lead to a variety of emotional and physical problems. It affects more than 17 million American adults, or about 6.8% of the U.S. population age 18 and older in a given year, and is one of the most common, but serious, mood disorders impacting people of all ages, races, and socioeconomic status.
“Our ongoing research into the treatment and management of depression, and other mood disorders, is driven by an ultimate goal of transforming the lives of people suffering from these conditions,” said
About the placebo-controlled pivotal Phase 2 trial of SAGE-217 in MDD
In the randomized, double-blind, parallel-group, placebo-controlled trial, 89 eligible patients (with a minimum total score of 22 on the Hamilton Rating Scale for Depression at baseline) were randomized in a 1:1 ratio to receive SAGE-217 capsules (30 mg) (n=45) or matching placebo (n=44). All doses of study drug were administered at night with food. The study consisted of a 14-day treatment period and a 4-week follow-up period. The mean HAM-D total scores at baseline were 25.2 for the SAGE-217 group and 25.7 for the placebo group (overall range 22-33), representing patients with moderate to severe MDD. Approximately 90% of patients in each group completed the study. The most common treatment emergent adverse events (≥5%) in the SAGE-217 group included headache (17.8%), nausea (11.1%), dizziness (11.1%), and somnolence (6.7%).
About Major Depressive Disorder
Major depressive disorder (MDD) is a common but serious mood disorder in which people experience depressive symptoms that impair their social, occupational, educational or other important functioning, such as a depressed mood or loss of interest or pleasure in daily activities, consistently for at least a two-week period. It is estimated that approximately 17 million people in the U.S. suffer from MDD each year. While antidepressants are widely used to treat MDD, large-scale studies have demonstrated the need for additional therapies.
SAGE-217 is a next generation positive allosteric modulator that has been optimized for selectivity to synaptic and extrasynaptic GABAA receptors and has a pharmacokinetic profile intended for periods of daily oral dosing. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. SAGE-217 is currently being developed for major depressive disorder, postpartum depression, and certain other mood disorders.
Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: our views, statements and expectations regarding: the potential timing for reporting results from the MOUNTAIN study; the goals of our development program for SAGE-217, and the potential to generate data sufficient to file for regulatory approval; the potential of SAGE-217 as a future treatment option in the treatment of MDD and PPD, and the potential to change treatment paradigms and benefit patients, if SAGE-217 is successfully developed and approved; our estimates as to the number of people in the U.S. who suffer from MDD; and the goals and vision for our programs and potential of our business. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may not be successful in our development of SAGE-217 or any of our other current or future product candidates in any indication we are currently pursuing or may in the future pursue; success in earlier clinical trials or nonclinical studies may not be repeated or observed in ongoing or future studies; ongoing and future clinical or nonclinical results may generate negative results or results that are otherwise different than we expect which may cause a delay or curtailment of future development efforts or may not support further development or be sufficient to file for or gain regulatory approval; we may decide that a development pathway in one or more indications is no longer feasible or advisable or that the unmet need no longer exists; the